

Heather A Wakelee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7725269/publications.pdf>

Version: 2024-02-01

160
papers

11,047
citations

50170

46
h-index

32761

100
g-index

162
all docs

162
docs citations

162
times ranked

14382
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, e148-e153.	1.1	16
2	Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 87-96.	3.0	10
3	Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. <i>Journal of Thoracic Oncology</i> , 2022, 17, 116-129.	0.5	50
4	Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females. <i>Journal of the National Cancer Institute</i> , 2022, 114, 78-86.	3.0	23
5	Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 264-272.	1.1	11
6	Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. <i>Clinical Lung Cancer</i> , 2022, 23, e210-e221.	1.1	11
7	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100497.	0.7	4
8	Abstract PO-130: Disparities in risk of second primary lung cancer among lung cancer patients in the United States. , 2022, , .		0
9	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <i>ALK</i> -Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. <i>Clinical Cancer Research</i> , 2022, 28, 2506-2516.	3.2	19
10	Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100274.	0.6	1
11	In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?" <i>Journal of Thoracic Oncology</i> , 2022, 17, e12-e14.	0.5	0
12	Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.4	1
13	The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 618-625.	3.0	13
14	Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	7
15	Ancestry-based differences in gene alterations in non-small cell lung cancer: Real-world data using genetic ancestry analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9125-9125.	0.8	1
16	Genomic characterization of thymic epithelial tumor from real-world data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8587-8587.	0.8	1
17	PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. <i>Clinical Lung Cancer</i> , 2021, 22, e329-e335.	1.1	4
18	Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e153-e156.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e193-e200.	1.1	12
20	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 395-403.	0.5	33
21	Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. <i>Clinical Chemistry</i> , 2021, 67, 534-542.	1.5	14
22	Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series. <i>Translational Lung Cancer Research</i> , 2021, 10, 487-495.	1.3	19
23	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100114.	0.6	11
24	Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2021, 3, 137-139.	1.7	55
25	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021, 26, 523-532.	1.9	4
26	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	6.6	80
27	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i> . <i>Cancer Discovery</i> , 2021, 11, 1736-1753.	7.7	59
28	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. <i>Clinical Lung Cancer</i> , 2021, 22, 201-209.	1.1	24
29	Metabolomic profiling for second primary lung cancer: A pilot case-control study. <i>Lung Cancer</i> , 2021, 155, 61-67.	0.9	8
30	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 868-872.	0.5	42
31	Integrating Electronic Health Record, Cancer Registry, and Geospatial Data to Study Lung Cancer in Asian American, Native Hawaiian, and Pacific Islander Ethnic Groups. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1506-1516.	1.1	8
32	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	0.5	79
33	Tobacco Smoking and Risk of Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 968-979.	0.5	54
34	Radiological tumour classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , 2021, 3, 787-798.	8.3	41
35	Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab076.	1.4	8
36	A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, e59-e60.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2029-2039.	0.5	34
38	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase ⁺ Positive Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1617.	3.4	105
39	Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. <i>Clinical Lung Cancer</i> , 2021, 22, e673-e677.	1.1	2
40	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1479-1489.	0.5	2
41	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	0.5	274
42	Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 153-162.	1.5	4
43	Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. <i>Neuro-Oncology Advances</i> , 2021, 3, v52-v62.	0.4	4
44	Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1994-1998.	0.5	7
45	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 274-281.	3.2	75
46	KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93
47	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	7.7	6
48	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
49	Everolimus in the treatment of metastatic thymic epithelial tumors. <i>Lung Cancer</i> , 2020, 149, 97-102.	0.9	12
50	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. <i>Onc Immunology</i> , 2020, 9, 1824645.	2.1	31
51	TERA-VOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	7.7	51
52	A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100174.	0.7	10
53	Adjuvant Chemotherapy. <i>Thoracic Surgery Clinics</i> , 2020, 30, 179-185.	0.4	1
54	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379

#	ARTICLE	IF	CITATIONS
55	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4785-4794.	3.2	63
56	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
57	Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. <i>Lung Cancer</i> , 2019, 137, 71-75.	0.9	11
58	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019, 97, 102-111.	0.9	67
59	Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. <i>Lung Cancer</i> , 2019, 133, 144-150.	0.9	90
60	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 42-45.	0.9	37
61	Tumor Heterogeneity and Testing Discrepancy Confound ROS1 Detection in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e111-e113.	0.5	1
62	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 946-953.	0.8	377
63	Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes"; <i>Lung Cancer</i> , 2019, 137, 159-160.	0.9	2
64	Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e21-e24.	0.5	23
65	Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e208-e217.	1.1	9
66	Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. <i>Oncologist</i> , 2019, 24, 836-843.	1.9	34
67	Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 767-778.	0.5	24
68	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, 377-386.	1.1	0
69	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	0.5	134
70	Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. <i>Cancer Medicine</i> , 2018, 7, 1211-1220.	1.3	22
71	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 2771-2779.	3.2	141
72	Circulating tumor DNA testing in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 119, 42-47.	0.9	31

#	ARTICLE	IF	CITATIONS
73	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	3
74	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 219-227.	0.6	6
75	EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	8
76	Caution Needed for Analyzing the Risks of Second Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, e172-e173.	0.5	1
77	Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e581-e588.	1.1	22
78	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	0.5	515
79	A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 541-550.	1.1	3
80	Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California. <i>PLoS ONE</i> , 2018, 13, e0197146.	1.1	11
81	Case closed: another prophylactic cranial irradiation trial for stage 3 non-small cell lung cancer fails to improve overall survival. <i>Annals of Translational Medicine</i> , 2018, 6, S118-S118.	0.7	1
82	ERBB2 -Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 833-842.	0.5	86
83	Elusive Target of Angiogenesis in Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1269-1271.	0.8	5
84	Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 31-44.	0.9	6
85	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
86	Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years. <i>Lung Cancer</i> , 2017, 108, 140-149.	0.9	26
87	A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 173-182.	0.9	11
88	Reply to Comment on "Statin use and all-cancer survival: prospective results from the Women's Health Initiative". <i>British Journal of Cancer</i> , 2017, 116, e2-e2.	2.9	1
89	Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 50-59.	1.1	35
90	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 338-343.	0.3	29

#	ARTICLE	IF	CITATIONS
91	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
92	Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 16-21.	0.4	14
93	Monitoring Neutropenia for Cancer Patients at the Point of Care. <i>Small Methods</i> , 2017, 1, 1700193.	4.6	4
94	Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. <i>Current Treatment Options in Oncology</i> , 2017, 18, 71.	1.3	22
95	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1610-1623.	5.1	136
96	Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. <i>Journal of Thoracic Oncology</i> , 2017, 12, 129-136.	0.5	62
97	Risk Stratification for Second Primary Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2893-2899.	0.8	92
98	The J-ALEX trialâ€”is frontline alectinib a new standard of care?. <i>Journal of Thoracic Disease</i> , 2017, 9, 2242-2245.	0.6	1
99	A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8576-TPS8576.	0.8	4
100	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 241-241.	0.8	0
101	Pretreatment biopsy for thymic epithelial tumorsâ€”does histology subtype matter for treatment strategy?. <i>Journal of Thoracic Disease</i> , 2016, 8, 1895-1900.	0.6	4
102	Immunohistochemical analysis of lichenoid reactions in patients treated with antiâ€”PDâ€”1 and antiâ€”PDâ€”1 therapy. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 339-346.	0.7	101
103	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. <i>Clinical Therapeutics</i> , 2016, 38, 1567-1576.	1.1	11
104	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8379-E8386.	3.3	90
105	The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1371-1382.	1.1	81
106	Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. <i>International Journal of Cancer</i> , 2016, 139, 2178-2192.	2.3	31
107	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	0.5	49
108	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	5.8	520

#	ARTICLE	IF	CITATIONS
109	Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 72.	2.0	14
110	Lung Cancer Survival Among Chinese Americans, 2000 to 2010. <i>Journal of Global Oncology</i> , 2016, 2, 30-38.	0.5	24
111	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422.	0.5	101
112	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	1.9	119
113	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 115, 129-135.	2.9	80
114	Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. <i>Gerontologist</i> , The, 2016, 56, S102-S111.	2.3	18
115	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016, 17, 10-17.e1.	1.1	30
116	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
117	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016, 34, 547-555.	9.4	837
118	Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study. <i>Annals of the American Thoracic Society</i> , 2016, 13, 58-66.	1.5	44
119	Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 989-993.	0.9	19
120	Lung Cancer in Never Smokers. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 43-57.	0.8	122
121	Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. <i>Journal of Clinical Oncology</i> , 2016, 34, 360-368.	0.8	29
122	A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3019-3019.	0.8	27
123	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1004-1013.	0.5	44
124	Novel Treatments for Thymoma and Thymic Carcinoma. <i>Frontiers in Oncology</i> , 2015, 5, 267.	1.3	1
125	Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1745-1753.	0.5	100
126	ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. <i>Cancer Epidemiology</i> , 2015, 39, 307-312.	0.8	21

#	ARTICLE	IF	CITATIONS
127	Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. <i>American Journal of Ophthalmology</i> , 2015, 160, 799-805.e1.	1.7	68
128	Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. <i>Lung Cancer</i> , 2015, 89, 280-286.	0.9	18
129	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. <i>Lung Cancer</i> , 2015, 90, 1-7.	0.9	14
130	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 366-373.	1.1	23
131	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. <i>Lung Cancer</i> , 2015, 87, 34-38.	0.9	27
132	GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. <i>Anticancer Research</i> , 2015, 35, 669-76.	0.5	5
133	Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2250-2265.	1.1	38
134	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. <i>Nature Medicine</i> , 2014, 20, 548-554.	15.2	1,771
135	Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy. <i>Seminars in Oncology</i> , 2014, 41, 40-56.	0.8	46
136	Prolonged Survival of Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. <i>Clinical Lung Cancer</i> , 2014, 15, 202-206.	1.1	68
137	Review of the current targeted therapies for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 576.	0.9	59
138	miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma. <i>Chest</i> , 2013, 144, 1632-1643.	0.4	50
139	Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?: Response. <i>Chest</i> , 2013, 144, 1971-1972.	0.4	0
140	Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 403-10.	1.3	36
141	Smoking and estrogen plus progestin (E+P) and lung cancer incidence and mortality.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1524-1524.	0.8	0
142	Management of early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 315.	1.3	1
143	A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 439006) in Previously Treated Non-Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1574-1582.	0.5	48
144	Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 231-237.	0.4	66

#	ARTICLE	IF	CITATIONS
145	Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 52-58.	1.1	83
146	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 815-824.	1.1	6
147	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 563-571.	1.1	16
148	Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 545-554.	1.1	25
149	Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. <i>Clinical Lung Cancer</i> , 2009, 10, 395-404.	1.1	4
150	Cooperative Group Research Efforts in Lung Cancer: Focus on Early-Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 9-15.	1.1	6
151	Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 346-351.	1.1	21
152	Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 198-203.	0.4	10
153	Antibodies to Vascular Endothelial Growth Factor in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, S113-S118.	0.5	15
154	Lung Cancer Incidence in Never Smokers. <i>Journal of Clinical Oncology</i> , 2007, 25, 472-478.	0.8	498
155	Changes in the natural history of nonsmall cell lung cancer (NSCLC)—Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. <i>Cancer</i> , 2006, 106, 2208-2217.	2.0	53
156	Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. <i>Journal of Thoracic Oncology</i> , 2006, 1, 441-6.	0.5	43
157	Activity of Novel Cytotoxic Agents in Lung Cancer: Etoposides and Topoisomerase I Inhibitors. <i>Clinical Lung Cancer</i> , 2005, 7, S6-S12.	1.1	7
158	Targeting Angiogenesis with Vascular Endothelial Growth Factor Receptor Small-Molecule Inhibitors: Novel Agents with Potential in Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, S31-S38.	1.1	23
159	Docetaxel in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 13-24.	1.1	7
160	Novel approaches for the treatment of small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 499-518.	0.9	7